Download PDF
Der Nuklearmediziner 2004; 27(4): 304-314
DOI: 10.1055/s-2004-832457
© Georg Thieme Verlag Stuttgart · New York

PET/CT zur Diagnostik des Prostatakarzinomes

PET/CT in Detecting Prostate CancerN. M. Blumstein1 , S. N. Reske1
  • 1Abteilung Nuklearmedizin, Universitätsklinikum Ulm
Further Information

Publication History

Publication Date:
14 February 2005 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Fusionsbildgebung der PET und der CT in einem Kombinationsgerät hat wegen ihrer vielseitigen PET-basierten Detektionsprinzipien mit anatomisch hochauflösender und präziser CT-basierter morphologischer Bildgebung ein hohes klinisches und wissenschaftliches Potenzial. Dieser Beitrag soll einen Ausblick über die Einsatzmöglichkeiten der PET/CT-Bildgebung im Staging und Restaging bei Patienten mit Prostatakarzinom vor dem Hintergrund des komplexen Krankheitsbildes und den derzeitigen Behandlungsrichtlinien darlegen.

Abstract

Acquisition of PET and CT images in a combined scanner allow accurate PET based metabolic imaging in a combination with high resolution and anatomical precise CT-based morphologic imaging. The short review summarises clinical indications and the potential of 11C-cholin PET/CT in detecting prostate cancer.

Schlüsselwörter

PET/CT - Onkologie - Prostatakarzinome

Key words

PET/CT - oncology - prostate cancer

Literatur

  • 1 Grönberg H. Prostate cancer epidemiology.  Lancet. 2003;  631 859-864
    PubMedGoogle Scholar
  • 2 Koch K. PSA-Test und Karzinom - Ein Beispiel für das Dilemma der Früherkennung.  Deutsches Ärzteblatt. 2003;  100 2486-2488
    PubMedGoogle Scholar
  • 3 Robert Koch Institut .Krebs in Deutschland. online 21.3.2003
    Google Scholar
  • 4 Rifkin M D. Prostate Cancer: The diagnostic dilemma and the place of imaging in detection and staging.  World J Urol. 1998;  16 76-80
    CrossrefPubMedGoogle Scholar
  • 5 Dhom G. Prostata. In: Dörr W, Seiffert G (Hrsg). Pathologie des männlichen Genitale. Springer, Berlin, Heidelberg 1991; 455-642
    Google Scholar
  • 6 Pienta K J, Esper P S. Risk factors for prostate cancer.  Ann Intern Med. 1993;  118 793-803
    PubMedGoogle Scholar
  • 7 Sanchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: An autopsy study.  Prostate. 2003;  54 238-247
    CrossrefPubMedGoogle Scholar
  • 8 Golz R, Störkel S. Pathologische Anatomie maligner Tumoren der Prostata. In: Hinkelbein W, Miller K, Wiegel T (Hrsg). Prostatakarzinom. Urologische und strahlentherapeutische Aspekte. Springer, Berlin, Heidelberg 1999; 13
    Google Scholar
  • 9 Bostwick D G. Staging prostate cancer - 1997: current methods and limitations.  Eur Urol. 1997;  32 (Suppl 3) 2-14
    PubMedGoogle Scholar
  • 10 Helpap B. Prognostic factors of prostatic carcinoma.  Pathologe. 1998;  19 42-52
    CrossrefPubMedGoogle Scholar
  • 11 Voges G E. Das klinisch organbegrenzte, radikal operierte Adenokarzinom der Prostata. Habilitationsschrift. Johann Gutenberg-Universität, Mainz 1992
    Google Scholar
  • 12 McNeal J E. Normal and pathologic anatomy of prostate.  Urology. 1981;  17 (Suppl 3) 11-16
    PubMedGoogle Scholar
  • 13 Bostwick D G, Cooner W H, Denis L, Jones G W, Scardino P T, Murphy G P. The association of benign prostatic hyperplasia and cancer of the prostate.  Cancer. 1992;  70 (Suppl 1) 291-301
    CrossrefPubMedGoogle Scholar
  • 14 Wittekind C, Meyer H J, Bootz F. TNM-Klassifikation maligner Tumore. 6. Aufl., Springer, Berlin, Heidelberg 2003
    Google Scholar
  • 15 de la Monte S M, Moore G W, Hutchins G M. Metastatic behavior of prostate cancer. Cluster analysis of patterns with respect to estrogen treatment.  Cancer. 1986;  58 985-993
    PubMedGoogle Scholar
  • 16 Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved.  Cancer. 1984;  54 3078-3084
    PubMedGoogle Scholar
  • 17 Kastendieck H, Bressel M, Henke A, Husselmann H. The incidence of regional lymph node metastases in operable prostatic carcinoma.  Dtsch Med Wochenschr. 1980;  105 1348-1354
    PubMedGoogle Scholar
  • 18 Wirth S, Froschermaier S, Manseck A. Die Rolle des PSA in der Diagnostik und des Prostatakarzinoms. In: Hinkelbein W, Miller K, Wiegel T (Hrsg). Prostatakarzinom. Urologische und strahlentherapeutische Aspekte. Springer, Berlin, Heidelberg 1999; 106
    Google Scholar
  • 19 www.awmf-Leitlinien.de
  • 20 Schroeder F. The European randomized study of screening for prostate cancer (ERSPC).  Br J Urol. 1997;  79 68-71
    PubMedGoogle Scholar
  • 21 www.eua.org
  • 22 Catalona W J, Smith D S. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.  J Urol. 1994;  152 1837-1842
    PubMedGoogle Scholar
  • 23 Morgan W R, Bergstralh E J, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer.  Urology. 1993;  41 113-120
    CrossrefPubMedGoogle Scholar
  • 24 Partin A W, Pound C R, Clemens J Q, Epstein J I, Walsh P C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.  Urol Clin North Am. 1993;  20 713-725
    PubMedGoogle Scholar
  • 25 Wiegel T. The long-term results of radiotherapy in prostatic carcinoma recurrences after radical prostatectomy.  Strahlenther Onkol. 1998;  174 643-644
    PubMedGoogle Scholar
  • 26 Keyser D, Kupelian P A, Zippe C D, Levin H S, Klein E A. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?.  Int J Radiat Oncol Biol Phys. 1997;  38 723-729
    CrossrefPubMedGoogle Scholar
  • 27 Geinitz H, Zimmermann F, von Wedel E, Thamm R, Busch R, Feldmann H J, Molls M. Biochemical control after conformal, 3-dimensional radiotherapy of prostatic carcinoma.  Strahlenther Onkol. 2002;  178 369-377
    CrossrefPubMedGoogle Scholar
  • 28 Noldus J, Stamey T A. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.  J Urol. 1996;  155 232-237
    PubMedGoogle Scholar
  • 29 Wolf J S, Cher M, Dall'era M, Presti J C, Hricak H, Carroll P R. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy.  J Urol. 1995;  153 993-999
    PubMedGoogle Scholar
  • 30 Bluestein D L, Bostwick D G, Bergstralh E J, Oesterling J E. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.  J Urol. 1994;  151 1315-1320
    PubMedGoogle Scholar
  • 31 Kattan M W, Eastham J A, Stapleton A M, Wheeler T M, Scardino P T. Apreoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.  J Natl Cancer Inst. 1998;  90 766-771
    CrossrefPubMedGoogle Scholar
  • 32 Partin A W, Mangold L A, Lamm D M, Walsh P C, Epstein J I, Pearson J D. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.  Urology. 2001;  58 843-848
    CrossrefPubMedGoogle Scholar
  • 33 Wawroschek F, Vogt H, Weckermann D, Wagner T, Hamm M, Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer.  J Urol. 2001;  166 1715-1719
    CrossrefPubMedGoogle Scholar
  • 34 Miller J I, Ahmann F R, Drach G W, Emerson S S, Bottaccini M R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.  J Urol. 1992;  147 956-961
    PubMedGoogle Scholar
  • 35 Dinges S, Deger S, Koswig S, Boehmer D, Schnorr D, Wiegel T, Loening S A, Dietel M, Hinkelbein W, Budach V. High-dose rate interstitial with external beam irradiation for localized prostate cancer-results of a prospective trial.  Radiother Oncol. 1998;  48 197-202
    CrossrefPubMedGoogle Scholar
  • 36 Lawton C A, Winter K, Byhardt R, Sause W T, Hanks G E, Russell A H, Rotman M, Porter A, McGowan D G, DelRowe J D, Pilepich M V. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group.  Int J Radiat Oncol Biol Phys. 1997;  38 931-939
    CrossrefPubMedGoogle Scholar
  • 37 D'Amico A V, Whittington R, Malkowicz S B, Cote K, Loffredo M, Schult D, Chen M H, Thomaszewski J E, Renshaw A A, Wein A, Richie J P. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically lcalized prostate carcinoma in the prostate specific antigen era.  Cancer. 2002;  95 211-214
    CrossrefPubMedGoogle Scholar
  • 38 Zincke H, Utz D C, Taylor W F. Bilateral pelvic lymphadenectomy and radicalprostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and in disease progression.  J Urol. 1986;  135 1199-1205
    PubMedGoogle Scholar
  • 39 Catalona W, Rickie J. et al . Comparison of digital rectal examination an serum PSA in the early detection of prostae cancer.  Int J Cancer. 2002;  98 266-273
    PubMedGoogle Scholar
  • 40 Zincke H, Bergstralh E J, Blute M L, Myers R P, Barrett D M, Lieber M M, Marti S K, Oesterling J E. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1 143 patients from a single institution.  J Clin Oncol. 1994;  11 2254-2263
    PubMedGoogle Scholar
  • 41 Breul J. Fehler bei der präoperativen Betsimmung des lokalen Tumorstadiums bei der radikalen Prostatektomie. In: Hartung P, Kropp W (Hrsg). Urologische Beckenchirurgie. Springer, Berlin, Heidelberg 1991
    Google Scholar
  • 42 Partin A W, Pound C R, Clemens J Q, Epstein J I, Walsh P C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.  Urol Clin North Am. 1993;  20 713-725
    PubMedGoogle Scholar
  • 43 Wirth M, Tyrrell C, Wallace M, Delaere K P, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes C F, Borchers T M, Morris T, Stone A. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localizedor locally advanced prostate cancer significantly reduces the risk of disease progression.  Urology. 2001;  58 146-151
    CrossrefPubMedGoogle Scholar
  • 44 Cadeddu J A, Partin A W, DeWeese T L, Walsh P C. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy.  J Urol. 1998;  159 173-177
    PubMedGoogle Scholar
  • 45 Pisansky T M, Kozelsky T F, Myers R P, Hillman D W, Blute M L, Buskirk S J, Cheville J C, Ferrigni R G, Schild S E. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer.  J Urol. 2000;  163 845-850
    PubMedGoogle Scholar
  • 46 Höcht S, Wiegel T, Schostak M, Hinkelbein W. Adjuvant and salvage radiotherapy after radical prostatectomy.  Onkologie. 2002;  25 201-206
    CrossrefPubMedGoogle Scholar
  • 47 Wiegel T, Bressel M, Arps H, Hubener K H. Radiotherapy of local recurrence following radical prostatectomy.  Strahlenther Onkol. 1992;  168 333-336
    PubMedGoogle Scholar
  • 48 Takayama T K, Krieger J N, True L D, Lange P H. Recurrent prostate cancer despite undetectable prostate specific antigen.  J Urol. 1992;  148 1541-1542
    PubMedGoogle Scholar
  • 49 Wirth M. Die Rolle des PSA in der Diagnostik des Prostatakarzinoms. In: Hinkelbein W, Miller K, Wiegel T (Hrsg). Prostatakarzinom. Urologische und strahlentherapeutische Aspekte. Springer, Berlin, Heidelberg 1999; 105
    Google Scholar
  • 50 Link P, Freiha F S, Stamey T A. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy.  J Urol. 1991;  145 532-534
    PubMedGoogle Scholar
  • 51 Wu J J, King S C, Montana G S, McKinstry C A, Anscher M S. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen.  Int J Radiat Oncol Biol Phys. 1995;  32 317-323
    CrossrefPubMedGoogle Scholar
  • 52 Partin A W, Pearson J D, Landis P K, Carter H B, Pound C R, Clemens J Q, Epstein J I, Walsh P C. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.  Urology. 1994;  43 649-659
    CrossrefPubMedGoogle Scholar
  • 53 Denis L J, Carnelro de Moura J L, Bono A, Sylvester R, Whelan P, Newling D, Depauw M. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.  Urology. 1993;  42 119-129
    CrossrefPubMedGoogle Scholar
  • 54 Spigelman S S, McNeal J E, Freiha F S, Stamey T A. Rectal examination in volume determination of carcinoma of the prostate: clinical and anatomical correlations.  J Urol. 1986;  136 1228-1230
    PubMedGoogle Scholar
  • 55 Devonec M, Fendler J P, Monsallier M, Mouriquand P, Maquet J H, Mestas J L, Dutrieux-Berger N, Perrin P. The significance of the prostatic hypoechoic area: results in 226 ultrasonically guided prostatic biopsies.  J Urol. 1990;  143 316-319
    PubMedGoogle Scholar
  • 56 Silverman J M, Krebs T L. MR imaging evaluation with a tranrectal surface coil of local recurrence of prostatic cancer in man who have undergone radical prostatectomy.  AJR Am J Roentgenol. 1997;  168 379-385
    PubMedGoogle Scholar
  • 57 Kurhanewicz J, Vigneron D B, Hricak H, Parivar F, Nelson S J, Shinohara K, Carroll P R. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.  Radiology. 1996;  200 489-496
    PubMedGoogle Scholar
  • 58 Kramer S, Gorich J, Gottfried H W, Riska P, Aschoff A J, Rillinger N, Brambs H J, Sokiranski R. Sensitivity of computed tomography in detecting of local recurrence of prostatic carcinoma following radical prstatectomy.  Br J Radiol. 1997;  70 995-999
    CrossrefPubMedGoogle Scholar
  • 59 Roscigno M, Scattoni V, Raber M, Consonni P, Montorsi F, Pasta A, Bertini R, Colombo R, Da Pozzo L, Freschi M, Rigatti P. Role of prostate fossa ultrasonography in the diagnosis of local recurrence after radical prostatectomy in case of PSA failure.  Arch Ital Urol Androl. 2002;  74 304-308
    PubMedGoogle Scholar
  • 60 Schiebler M L, Schnall M, Pollack H M, Lenkinski R E, Tomaszewski J E, Wein A J. Current role of MR imaging in the staging of Adenocarcimoma of the prostate.  Radiology. 1993;  189 339-352
    PubMedGoogle Scholar
  • 61 Jager G J, Barentsz J O, Oosterhof G O, Witjes J A, Ruijs S JH. Pelvic adenopathia in prostatic and bladder cancer: MR imaging with a three-dimensional T1-weighted magnetization-prepared-rapid gradient-echo sequence.  AJR. 1996;  176 1503-1507
    PubMedGoogle Scholar
  • 62 Swindle P W, Kattan M W, Scardino P T. Markers and meaning of primary treatment failure.  Urol Clin North Am. 2003;  30 377-401
    CrossrefPubMedGoogle Scholar
  • 63 Pound C R, Partin A W. What does prostate specific antigen recurrence mean?.  Curr Urol Rep. 2002;  1 28-35
    PubMedGoogle Scholar
  • 64 Scherr D, Swindle P W, Scardino P T. National comprehensive cancer network guidelines for the management of prostate cancer.  Urology. 2003;  61 (Suppl 2 A) 14-24
    CrossrefPubMedGoogle Scholar
  • 65 Kotzerke J, Prang J, Neumaier B, Volkmer B, Guhlmann A, Kleinschmidt K, Hautmann R, Reske S N. Experience with carbon-11 choline positron emission tomography in prostate carcinoma.  Eur J Nucl Med. 2000;  27 1415-1419
    CrossrefPubMedGoogle Scholar
  • 66 Kotzerke J, Volkmer B G, Neumaier B, Gschwend J EA, Kleinschmidt K, Hautmann R E, Reske S N. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer.  Eur J Nucl med Mol Imaging. 2002;  29 1380-1384
    CrossrefPubMedGoogle Scholar
  • 67 Kotzerke J, Volkmer B G, Glatting G, Hoff J, Gschwend J E, Messer P, Reske S N, Neumaier B. Intraindividual comparison of [11C]acetate and [11C]choline PET for Detection of metastases of prostate cancer.  Nuklearmedizin. 2003;  42 25-30
    PubMedGoogle Scholar
  • 68 Oyama N, Akino H, Kanamaru H, Suzuky J, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K. 11C-acetate PET imaging of prostate cancer.  J Nucl Med. 2002;  43 181-186
    PubMedGoogle Scholar
  • 69 Oyama N, Miller T R, Dehdashti F, Siegel B A, Fischer K C, Michalski J M, Kibel A S, Andriole G L, Picus J, Welch M J. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.  J Nucl Med. 2000;  44 549-555
    PubMedGoogle Scholar
  • 70 Hara T, Kosaka N, Kondo T, Kishi H, Kobori O. Imaging of brain tumor, lung cancer; esophagus cancer, colon cancer, prostate cancer, and bladder cancer with [11C]choline.  J Nucl Med. 1997;  38 (Suppl) 250
    PubMedGoogle Scholar
  • 71 Hautzel H, Müller-Mattheis V, Herzog H, Roden W, Coenen H H, Ackermann R, Müller-Gärtner H-W, Krause B J. Neue Perspektiven in der metabolischen Bildgebung beim Prostatakarzinom: Die 11C-Azetat Positronen Emissions-Tomographie.  Urologe A. 2002;  41 569-576
    CrossrefPubMedGoogle Scholar
  • 72 Frazier H A, Robertson J E, Humphrey P A, Paulson D F. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.  J Urol. 1993;  149 516-518
    PubMedGoogle Scholar
  • 73 Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M, Matarrese M, Matei D V, De Corbelli F, Del Maschio A, Rocco F, Rigatti P, Fazio F. Value of [11C]choline positron emission tomography for restaging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.  J Urol. 2003;  169 1337-1340
    CrossrefPubMedGoogle Scholar
  • 74 De Jong I J, Pruim J, Elsinga P H, Vaalburg W, Mensink H J. Preoperative staging of pelvic lymph nodes in Prostate Cancer by 11C-Cholin PET.  J Nucl Med. 2003;  44 331-335
    PubMedGoogle Scholar
  • 75 De Jong I J, Pruim J, Elsinga P H, Vaalburg W, Mensink H J. Visualisation of prostate cancer with 11C-choline positron emission tomography.  Eur Urol. 2002;  42 18-23
    CrossrefPubMedGoogle Scholar
  • 76 De Jong I J, Pruim J, Elsinga P H, Vaalburg W, Mensink H J. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.  Eur Urol. 2003;  44 32-38
    CrossrefPubMedGoogle Scholar
  • 77 Dhingsa R, Qayyum A, Coakley F V, Lu Y, Jones K D, Swanson M G, Carroll P R, Hricak H, Kurhanewicz J. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy.  Radiolog. 2004;  230 215-220
    PubMedGoogle Scholar

Dr. Norbert M. Blumstein

Abteilung Nuklearmedizin, Universitätsklinikum Ulm

Robert Koch-Str. 8

89081 Ulm

Phone: 00 49/(0)7 31/50 02 45 00

Fax: 00 49/(0)7 31/50 02 45 03

Email: norbert-manfred.blumstein@medizin.uni-ulm.de